Opportunity Information: Apply for RFA AI 16 028
Apply for RFA AI 16 028
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Understanding HIV Rebound (P01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.855, 93.856,.
- This funding opportunity was created on Apr 19, 2016 and posted on Apr 19, 2016.
- Applicants must submit their applications by Jul 29, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Understanding HIV Rebound (P01) funding opportunity (RFA AI 16 028) is a National Institutes of Health (NIH) grant announcement from the U.S. Department of Health and Human Services (HHS), designed to fund coordinated, multi-disciplinary Program Project (P01) research efforts focused on why HIV returns in the blood after being suppressed. The central scientific goal is to identify and explain the mechanisms, biomarkers, and biological pathways that are linked to HIV viremia rebound, meaning the reappearance or rapid rise of detectable virus after a period in which antiretroviral therapy (ART) had kept viral levels fully suppressed. This FOA is positioned to support team-based projects where multiple related subprojects and shared cores work together around a unified theme, rather than isolated single-investigator studies.
The research scope is specifically anchored in situations where rebound can be observed and analyzed in a structured way, and it highlights three main study contexts. First, it encourages studies in HIV- or SIV-positive hosts who started ART very early after infection, maintained long-term full viral suppression, and then later stopped therapy, creating an opportunity to examine what predicts or drives rebound once drug pressure is removed. Second, it supports work in HIV- or SIV-positive hosts who are receiving an intervention intended to control or delay rebound, which can include strategies that aim to extend the time to rebound or blunt the magnitude of returning viremia. Third, it includes hosts receiving interventions aimed at diminishing or eradicating viral reservoirs, reflecting cure-oriented approaches where the key question is whether reservoir-targeting strategies measurably change rebound dynamics and what biological signals correspond to those changes. By including both human HIV and animal SIV models, the announcement implicitly supports translational work that can combine controlled experimental systems with clinically relevant observations.
From a practical funding perspective, the opportunity is offered as a discretionary grant with an activity category in health, and it is associated with CFDA numbers 93.242, 93.855, and 93.856. The award ceiling is listed as $1,000,000, indicating the maximum funding level expected per award under the announcement. The FOA was created and posted on April 19, 2016, with an original and current closing date of July 29, 2016. While the listing shows an “ExpectedAwards” field without a specified number, the structure and wording indicate competitive funding for a limited set of program projects that best address the FOA’s targeted scientific questions.
Eligibility is broad and includes many organization types that commonly apply to NIH research programs. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations other than small businesses; small businesses; and other applicants as clarified in the full eligibility text. This wide eligibility range signals an intent to attract strong, cross-sector teams, including academic, nonprofit, government, and industry-linked groups, as long as they can assemble the scientific breadth needed for a P01.
In essence, this FOA is aimed at accelerating progress toward HIV remission and cure strategies by funding integrated research programs that can explain the biology of rebound, discover measurable indicators that predict or track rebound, and map the pathways that interventions might alter. The emphasis on early-treated, long-suppressed individuals and on intervention studies reflects a practical focus on scenarios that are most informative for understanding reservoirs, immune control, viral persistence, and the triggers that allow virus to re-emerge when ART is interrupted or when cure-directed therapies are tested.
Frequently Asked Questions (FAQs): Understanding HIV Rebound (P01) - RFA AI 16 028
What is the Understanding HIV Rebound (P01) funding opportunity?
This is an NIH grant announcement from the U.S. Department of Health and Human Services (HHS) designed to support coordinated, multi-disciplinary Program Project (P01) research focused on understanding why HIV returns in the blood after having been suppressed by antiretroviral therapy (ART).
What is the FOA number for this opportunity?
The funding opportunity is titled "Understanding HIV Rebound (P01)" and is identified as RFA AI 16 028.
Which agency is offering this grant?
The opportunity is offered through the National Institutes of Health (NIH), within the U.S. Department of Health and Human Services (HHS).
What type of grant mechanism does this announcement support?
This FOA supports a Program Project (P01) mechanism. It is intended for team-based, coordinated research programs built around a unified theme, typically involving multiple related subprojects and shared cores working together.
What is the central scientific goal of the FOA?
The central goal is to identify and explain mechanisms, biomarkers, and biological pathways linked to HIV viremia rebound, meaning the reappearance or rapid rise of detectable virus after a period of full suppression on ART.
What does "HIV viremia rebound" mean in this context?
In this FOA, HIV viremia rebound refers to HIV returning to detectable levels in the blood (or rising rapidly) after ART had previously kept viral levels fully suppressed.
What kinds of studies does the FOA emphasize?
The FOA emphasizes research where rebound can be observed and analyzed in structured, informative contexts. It highlights three main study situations: (1) early ART initiation followed by long-term suppression and later ART interruption, (2) intervention studies intended to control or delay rebound, and (3) interventions aimed at diminishing or eradicating viral reservoirs.
What is the first main study context described in the FOA?
The first context involves HIV- or SIV-positive hosts who started ART very early after infection, maintained long-term full viral suppression, and then later stopped therapy. This setup creates an opportunity to study what predicts or drives rebound once drug pressure is removed.
What is the second main study context described in the FOA?
The second context involves HIV- or SIV-positive hosts receiving an intervention intended to control or delay rebound. This includes strategies aiming to extend the time to rebound or reduce the magnitude of returning viremia.
What is the third main study context described in the FOA?
The third context involves hosts receiving interventions aimed at diminishing or eradicating viral reservoirs. These are cure-oriented approaches that assess whether reservoir-targeting strategies change rebound dynamics and what biological signals correspond to those changes.
Does the FOA allow research in both humans and animals?
Yes. The FOA includes both human HIV and animal SIV models, supporting translational research that can combine controlled experimental systems with clinically relevant observations.
Why does the FOA include SIV models?
SIV models can provide controlled experimental settings that complement human observations, helping teams investigate mechanisms and pathways related to rebound in ways that may be difficult to study solely in clinical settings.
Is this FOA meant for single-investigator projects?
No. The FOA is positioned to support coordinated, multi-disciplinary P01 program projects with multiple related subprojects and shared cores, rather than isolated single-investigator studies.
What is the award ceiling for this opportunity?
The award ceiling is listed as $1,000,000, indicating the maximum funding level expected per award under this announcement.
How is this opportunity categorized from a funding perspective?
It is listed as a discretionary grant with an activity category in health.
What CFDA numbers are associated with this FOA?
The FOA is associated with CFDA numbers 93.242, 93.855, and 93.856.
When was this FOA posted?
The FOA was created and posted on April 19, 2016.
What is the closing date for applications?
The original and current closing date listed is July 29, 2016.
How many awards are expected under this FOA?
The listing shows an "ExpectedAwards" field without a specified number, suggesting competitive funding for a limited set of program projects that best address the FOA's targeted scientific questions.
Who is eligible to apply for this opportunity?
Eligibility is broad and includes many organization types, including government entities, higher education institutions, tribal governments and organizations, nonprofits, for-profits, small businesses, and other applicants as clarified in the full eligibility text.
Are state, county, and local governments eligible?
Yes. Eligible applicants include state governments, county governments, and city or township governments, as well as special district governments.
Are educational institutions eligible to apply?
Yes. Eligible applicants include independent school districts, public and state-controlled institutions of higher education, and private institutions of higher education.
Are tribal governments and tribal organizations eligible?
Yes. Eligibility includes federally recognized Native American tribal governments and other tribal organizations.
Are public housing authorities eligible?
Yes. Public housing authorities and Indian housing authorities are listed as eligible applicants.
Are nonprofit organizations eligible?
Yes. Nonprofit organizations with or without 501(c)(3) status are included as eligible (excluding institutions of higher education within those nonprofit categories as stated in the eligibility description).
Are for-profit organizations eligible?
Yes. For-profit organizations other than small businesses are eligible, and small businesses are also explicitly listed as eligible.
What is the intended impact or purpose of funding research under this FOA?
The FOA aims to accelerate progress toward HIV remission and cure strategies by funding integrated research programs that explain the biology of rebound, discover measurable indicators that predict or track rebound, and map the pathways that interventions may alter.
Why does the FOA emphasize early-treated, long-suppressed individuals?
The FOA emphasizes these populations because they offer especially informative scenarios for understanding viral reservoirs, immune control, viral persistence, and the triggers that allow virus to re-emerge when ART is interrupted.
What kinds of research outputs does the FOA highlight?
Based on the description, the FOA highlights identifying mechanisms, discovering biomarkers, and mapping biological pathways associated with HIV rebound, particularly in intervention and treatment interruption settings where rebound dynamics can be measured.
Browse more opportunities from the same category: Health
Next opportunity: Community Connect Grant Program
Previous opportunity: Haiti-Building the Capacity of Workers’ Organizations in the Apparel Sector
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 16 028
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 16 028) also looked into and applied for these:
| Funding Opportunity |
|---|
| The Use of mRNA for an HIV Envelope Vaccine (R41/R42) Apply for PA 16 208 Funding Number: PA 16 208 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Investigator-Initiated Clinical Sequencing Research (R01) Apply for PAR 16 209 Funding Number: PAR 16 209 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Nonhuman Primate Transplantation Tolerance (U01) Apply for RFA AI 16 007 Funding Number: RFA AI 16 007 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| BioMosaic: Enhancing surveillance, detection, risk assessment and response activities using a mapping and visualization tool Apply for CDC RFA CK14 140403CONT16 Funding Number: CDC RFA CK14 140403CONT16 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: Case Dependent |
| The National Institute on Aging (NIA) Late Onset of Alzheimer's Disease (LOAD) Family-Based Study (FBS) (U24) Apply for PAR 16 205 Funding Number: PAR 16 205 Agency: HHS-NIH11 Category: Health Funding Amount: $1,100,000 |
| Nonhuman Primate Transplantation Tolerance (U19) Apply for RFA AI 16 008 Funding Number: RFA AI 16 008 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| The Use of mRNA for an HIV Envelope Vaccine (R43/R44) Apply for PA 16 207 Funding Number: PA 16 207 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) Apply for PAR 16 210 Funding Number: PAR 16 210 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Pediatric Quality Measures Program (PQMP): Dissemination and Implementation of Child Health Quality Measures Cooperative Research Grants (U18) Apply for RFA HS 16 002 Funding Number: RFA HS 16 002 Agency: HHS-AHRQ Category: Health Funding Amount: $675,000 |
| Expansion of seasonal influenza vaccination programs in low and middle income countries Apply for CDC RFA IP16 1607 Funding Number: CDC RFA IP16 1607 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $2,000,000 |
| Program for Extramural/Intramural Alcohol Research Collaborations (U01) Apply for PAR 16 214 Funding Number: PAR 16 214 Agency: HHS-NIH11 Category: Health Funding Amount: $250,000 |
| Improving Physical Infrastructure Revisions of Center Grants (P40) Apply for RFA OD 16 010 Funding Number: RFA OD 16 010 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Support for Scale-Up of Community Package of High Impact Interventions - Phase II Apply for SOL 680 16 000007 Funding Number: SOL 680 16 000007 Agency: USAID-BEN Category: Health Funding Amount: $5,980,000 |
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Center Grants (P51) Apply for RFA OD 16 007 Funding Number: RFA OD 16 007 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Collaborations to Improve Identification and Care for Chronic Hepatitis B Virus (HBV) Infection among Persons in the United States who were Born in Countries with Intermediate-High (≥2%) HBV Prevalence Apply for CDC RFA PS14 141403CONT16 Funding Number: CDC RFA PS14 141403CONT16 Agency: HHS-CDC-NCHHSTP Category: Health Funding Amount: Case Dependent |
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Research Project Grants (R24) Apply for RFA OD 16 009 Funding Number: RFA OD 16 009 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Enhanced State Surveillance of Opioid-Involved Morbidity and Mortality Apply for CDC RFA CE16 1608 Funding Number: CDC RFA CE16 1608 Agency: HHS-CDC-NCIPC Category: Health Funding Amount: $775,000 |
| Continuing Enhanced National Surveillance for Prion Diseases in the United States Apply for CDC RFA CK12 120805CONT16 Funding Number: CDC RFA CK12 120805CONT16 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: Case Dependent |
| NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22) Apply for PAR 16 220 Funding Number: PAR 16 220 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) Apply for PAR 16 219 Funding Number: PAR 16 219 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 16 028", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.